James V. Cassella

James V. Cassella

Auto-generated profile, based on publicly available information

James V. Cassella

Sun Pharmaceutical Industries, Inc., Lexington, MA, US

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2024 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
BKBrett King
Brett King
MSMaryanne M Senna
Maryanne M Senna
NMNatasha Mesinkovska
Natasha Mesinkovska
CLCharles Lynde
Charles Lynde
MZMatthew Zirwas
Matthew Zirwas
JCJames Cassella
James Cassella
Alopecia areata (AA) is a hair loss disorder that can seriously impact quality of life. Janus kinase (JAK) inhibitors, including deuruxolitinib, have previously demonstrated significant hair regrowth in AA. The Phase 3 THRIVE-AA1 randomized, double-blinded, placebo-controlled trial (NCT04518995) evaluated safety and efficacy of the oral JAK1/JAK2 inhibitor deuruxolitinib in adult patients with AA. Patients aged 18-65 years with ≥50% hair loss were randomized to deuruxolitinib 8 mg BID, deuruxolitinib 12 mg BID, or placebo for 24 weeks. The primary endpoint was percentage of patients achieving Severity of Alopecia Tool (SALT) score ≤20. A key secondary endpoint was percentage of satisfaction of hair patient-reported outcome (SPRO) responders. Significantly higher proportions of patients taking deuruxolitinib met the primary endpoint (8 mg 29.6%; 12 mg 41.5% versus placebo 0.8%). Both deuruxolitinib doses achieved significant improvements in all secondary endpoints versus placebo, including SPRO (8 mg 42.1%; 12 mg 53.0% versus placebo 4.7%). Most treatment-emergent adverse events were mild or moderate, consistent with other oral JAK inhibitors. Further studies are required to understand longer-term safety, efficacy, and impact of treatment cessation. Both doses of deuruxolitinib were effective for hair regrowth. Patient satisfaction aligned with hair growth.

1 November 2020 in Journal of Investigative Dermatology Symposium Proceedings
Verified
Journal Article
Closed access
NMNatasha Mesinkovska
Natasha Mesinkovska
BKBrett King
Brett King
PMParadi Mirmirani
Paradi Mirmirani
JKJustin Ko
Justin Ko
JCJames Cassella
James Cassella

1 October 2003 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
RERichard L. Elliott
Richard L. Elliott
RORobert M. Oliver
Robert M. Oliver
JLJanet A. LaFlamme
Janet A. LaFlamme
MGMelissa L. Gillaspy
Melissa L. Gillaspy
MHMarlys Hammond
Marlys Hammond
JCJames V. Cassella
James V. Cassella

1 August 2010 in Journal of Aerosol Medicine and Pulmonary Drug Delivery
Verified
Journal Article
Closed access
KDKhe V. Dinh
Khe V. Dinh
DMDan J. Myers
Dan J. Myers
PNPeter D. Noymer
Peter D. Noymer
JCJames V. Cassella
James V. Cassella
Background: The Staccato® system employs a thermal vaporization technology to generate pure drug aerosols with a particle size optimized for alveolar deposition, leading to rapid absorption of the drug into the systemic circulation. Unlike most traditional aerosol-generation techniques, the particle size of the thermally generated aerosols is significantly affected by the airflow rate going through the device. The objective of this study was to determine the effects of flow rate and other operating conditions on predicted oropharyngeal and lung deposition when using the Staccato system. Methods: In vitro oropharyngeal deposition was measured at airflow rates of 15–80 L/min through the device. Oropharyngeal deposition was also measured for different inhalation profiles, different ambient temperatures and humidities, and device orientations. Deposition was measured using the Alberta geometry model, which was derived based on information available in the literature, CT scans of patients, and observations of living subjects. Results and Conclusions: Deposition in the oropharyngeal geometry was consistently ∼11% of the emitted dose throughout the entire range of flow rates. Such consistency in deposition was due to the fact that mass median aerodynamic diameter (MMAD) varied inversely as the square root of the flow rate, resulting in an approximately constant value for the inertial deposition parameter. Thus, an increase in flow rate, which would increase the momentum of a fixed particle size and generally lead to higher oropharyngeal deposition, was almost exactly counterbalanced by the accompanying decrease in MMAD. Results also showed that deposition in the oropharyngeal region was unaffected by other potentially relevant factors such as different airflow ramp rates, inhalation time, ambient temperature and relative humidity, and device orientations.

1 February 2003 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RERichard L. Elliott
Richard L. Elliott
RORobert M. Oliver
Robert M. Oliver
MHMarlys Hammond
Marlys Hammond
TPTerrell A. Patterson
Terrell A. Patterson
LSLi She
Li She
JCJames V. Cassella
James V. Cassella

1 June 2016 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
VUV. Uttamsineh
V. Uttamsineh
LPL. Pilja
L. Pilja
BGB. Grotbeck
B. Grotbeck
CBC.L. Brummei
C.L. Brummei
NUN. Uddin
N. Uddin
JCJ. Cassella
J. Cassella